

# IMCAS 2012 Commences with Three New Training Courses

By Michael Moretti, Editor and Birgit Hansen, Ph.D., Contributing Editor

**A**s a reputed professional training event, the *International Master Course on Aging Skin (IMCAS)*, taking place from January 26 – 29, 2012, at the Palais de Congres in Paris, France, will begin with three new events including a live injectables workshop, another live workshop focused on breast augmentation using autologous fat transfer and advancements in stem cell medicine.



The live, video-transmitted injectables training course will provide practical anatomy and injection techniques using cadavers and live patients for neurotoxin injection, dermal filling and volumetric filling purposes. Another live, video transmitted breast lipofilling workshop will focus on the best techniques of breast volume augmentation. Both of these workshops will run in parallel to the special full-day Anti-Aging Medicine course on Thursday. The third event is an entire day of scientific sessions dedicated to new developments in stem cell treatment for aesthetic medicine and surgery.

IMCAS's established team of course coordinators includes dermatologists David J. Goldberg, M.D., (New York, New York, U.S.) and Bernard Rossi, M.D., (Paris, France), plastic surgeon, Bernard Mole, M.D., (Paris, France) and IMCAS course director, Benjamin Ascher, M.D., a plastic surgeon in Paris, France. Working with the scientific committee, they have created a program featuring more than 60 scientific sessions, 32 sponsored symposia, 30 live demonstrations and 14 teaching courses on age-related skin pathologies, aesthetic and anti-aging medicine, as well as plastic surgery.

The unique Incubator Corner will once again provide aesthetic practitioners with an opportunity to present innovative ideas, and industry representatives a chance to evaluate the potential industrial development of these ideas. As well, leading industry executives and well-known economic experts will share their insight into global medical and surgical aesthetic market developments during the IMCAS Industry Tribune session.

Eight of the most creative, promising and useful clinical or surgical studies of the year will be awarded an IMCAS Clinical Study Innovation Award during the second La Nuit des IMCAS Awards. A

completely independent panel of judges will choose the winners.

Expecting more than 4,000 participants in its 14<sup>th</sup> year, IMCAS is still considered an important event among practitioners seeking education and insight into the vast amount of medical aesthetic information and technological developments. The scientific sessions will be accompanied by a tradeshow featuring more than 200 exhibitors using this first European based aesthetic event of the year to launch new products and present exciting industry news.

Anteis (Geneva, Switzerland), a leading innovator in aesthetic medicine, has received the Frost & Sullivan 2011 European New Product Innovation Award in Dermal Fillers. This award was granted for Anteis's recently launched Anteis Injection System (AIS), a breakthrough device that provides consistent, automated delivery of dermal fillers and re-hydration products. Since the density of tissue varies and often makes it challenging to smoothly inject at a constant flow, the AIS electronically adapts the pressure to maintain a very smooth and constant flow of the product during injection.



Anteis Injection System by Anteis

This system is proven to be highly effective in reducing pain, decreasing the amount of bruising, swelling and side effects commonly associated with manual injection techniques. Developed after careful analysis of the needs of practitioners and their patients, it has the potential to become a new industry standard.

Another IMCAS exhibitor and 2011 winner of the Frost & Sullivan European Technology Innovation of the Year Award in Dermal Fillers is AQTIS Medical (Utrecht, The Netherlands) for the Ellansé family of products. Scientifically designed to provide safety, biocompatibility and durability options, efficacy and ease of use in soft tissue augmentation, it is the first dermal filler family incorporating unique Tunable Longevity. Ellansé further differentiates itself through the characteristics of Sustained Performance and Total Bioresorbability (STAT) Technology.



Ellansé family of products by AQTIS Medical

Available in four different strengths, specifically S, M, L and E, every product consists of specific combinations of bio-resorbable polymer spherical microspheres and gels. Additionally, all four strengths have the same characteristics: smooth and spherical microspheres, particle size distribution (25  $\mu\text{m}$  – 50  $\mu\text{m}$ ), particle concentration, gel viscosity, particle gel homogeneity and injectability. However, the difference between the four strengths is their initial molecular weight of PCL polymer chains within the microspheres themselves, allowing for a predictable controlled bio-resorption and tunable longevity.

Teoxane Laboratoires (Paris, France and Geneva, Switzerland) has developed a new protocol to fight the first signs of aging such as a dull complexion, in addition to restoration of skin density and radiance in older patients. This regimen

## IMCAS 2012 Commences with Three New Training Courses

consists of a combination of light hyaluronic acid (HA) based dermal filling, deep hydration and rich nourishment of the skin with glycolic acid, minerals and antioxidants. After three sessions in intervals of three weeks the density of skin and its ability to reflect light is visibly restored.

Teosyal PureSense Redensity I is a special formulation based on a selection of ingredients that are all naturally present in the skin and known for their synergistic ability to proliferate re-densification of the dermis and antioxidant protection. A perfectly proportioned concentration of HA (15 mg/g) offers complete re-hydration of the skin. This is combined with a derma-restructuring complex, consisting of eight amino acids, three antioxidants and three minerals selected for their pharmaceutical grade, hypo-allergenic properties and compatibility with HA, to achieve total re-structuring of the dermis. In order to provide the highest patient comfort, this restructuring infiltration is performed in conjunction with lidocaine.



Teosyal PureSense Redensity I by Teoxane Laboratoires

Merz Aesthetics (Frankfurt, Germany) plans to announce the U.S. launch of its neurotoxin Xeomin (incobotulinumtoxin A) in spring 2012. Xeomin was recently FDA approved for the treatment of glabella lines. It is also approved for

temporary improvement in the appearance of glabella lines in 14 countries in the European Union (EU), including Germany, U.K., France, Italy and Spain, under the brand name Bocouture.



Xeomin by Merz Aesthetics

According to Dennis Condon, president and chief business officer of Merz Aesthetics, Inc. (San Mateo, California, U.S.), "The FDA approval of Xeomin is a significant milestone for Merz Aesthetics and a promising addition to our entire aesthetics franchise. We are confident that Xeomin will provide patients and physicians with a new option for improving the appearance of glabellar lines." Xeomin will be available in the U.S. in Spring 2012.

Syneron & Candela (Yokneam, Israel) will demonstrate Sublative Rejuvenation with the eMatrix system. Sublative Rejuvenation goes beyond fractional methods of skin resurfacing, using fractionated bi-polar radiofrequency (RF) technology to place heat energy effectively into the dermis, where it can produce significant dermal impact with minimal epidermal disruption.



eMatrix by Syneron & Candela

Sublative Rejuvenation gives practitioners the flexibility to treat skin texture, tone, laxity and scarring on even the darkest skin types without compromising patient comfort and safety. Each pulse delivers conducted RF energy via a grid of matrix spots to induce a skin injury. The intact tissue surrounding these spots supports an accelerated healing process.

eMatrix also features SelectPulse technology, which delivers a tunable impact of heating effects, including ablation, coagulation and residual heating. Depth of ablation and the extent of surrounding tissue coagulation can be controlled and customized to ensure that the exact degree of skin resurfacing required is provided.



AcuPulse by Lumenis

Lumenis (Yokneam, Israel) will present its recently launched AcuPulse CO<sub>2</sub> laser technology in a number of congress lectures, live demonstrations and workshops. With the new, patent pending MultiMode technology, AcuPulse offers the ability to perform both deep and superficial fractional cosmetic treatments using a single handpiece. With a simple, touch-point selection, treatment set-up and procedure time are reduced. AcuPulse with MultiMode technology is unique in its ability to support a wide-range of aesthetic and surgical specialties, delivering fast treatment with precise and consistent tissue effects.

## IMCAS 2012 Commences with Three New Training Courses



SP Dynamis by Fotona

Another combined, laser-based, fractional treatment approach to rejuvenate skin will be shown by Fotona (Ljubljana, Slovenia). The SP Dynamis system combines two highly optimized lasers in one system – a long pulsed Nd:YAG and a Variable Square Pulse Er:YAG.

Fotona's TwinLight fractional rejuvenation utilizes the characteristics of both wavelengths to significantly enhance success rates and shorten recovery times. This simple procedure improves skin smoothness and gives the skin a fresher, healthier look. Using fractional light to rejuvenate the skin can produce an effect that meets patient expectations, and offer a degree of control and efficacy that allows for precise sculpting of the skin. A full range of anti-aging treatments can be performed, from light touch-ups to deep, age erasing optical peels.



Sygmalift by MedixSysteme

Sygmalift from MedixSysteme (Nimes, France) combines fractional focal ultrasound with multi-flux and circular flux ultrasound energies, and a cold laser source for optimized facial remodeling, lifting and wrinkle reduction results. The main advantage of ultrasound-based treatment is the excellent penetration rate and the immediate effectiveness. This second generation of fractional ultrasound energy efficiently disrupts the adipose cell membranes for volume reduction, remodeling and restructuring in targeted areas, and is especially suitable for the reduction of double chins.



MultiFlex by Ellipse

Circular flux ultrasound is said to improve the extensibility of mature collagen found in older tissue. Sygmalift stimulates tissue regeneration and increases the elasticity of the skin. Finally the low level laser light therapy has been proven to accelerate the skin's natural healing process, and also stimulates the production of collagen for skin rejuvenation.

Ellipse (Denmark) plans to unveil the new Ellipse MultiFlex at IMCAS. The MultiFlex combines an Nd:YAG laser and a range of intense pulsed light (IPL) applicators to provide a scope of aesthetic treatments including skin rejuvenation and hair removal. Ellipse

MultiFlex only employs the wavelengths that are beneficial for each specific treatment, thus achieving safer and more effective results while using lower energies.

While there is no need for active cooling when using IPL, the Nd:YAG comes with integrated Soft-Cool technology. Furthermore, Ellipse MultiFlex has improved Clinical Intelligence software, which allows the physician to use his diagnostic skills to determine the ideal treatment and onboard documentation allows the physician to show the patient what to expect in terms of both endpoint and final results.

Norseld (Adelaide, Australia) will present the Copper Bromide (CuBr) multi-wavelength laser. Clinical trials have demonstrated the significant improvements achieved with CuBr in comparison to other vascular treatments. Today, the laser can produce both yellow and green light, and also blend the two wavelengths in order to treat a variety of skin conditions such as vascular, pigmented and bulky lesions, as well as melasma. These wavelengths also allow for photodynamic therapy.

"It has always been our goal to treat skin conditions with lasers, while avoiding discomfort to the patient. For over 20 years now, Norseld has treated thousands of patients with exceptional aesthetic results, and no collateral damage to surrounding tissue," said Peter Shute, managing director of Norseld. "The patent protected technology, Fast Edge MicroPulse (FEM), has been a key to the success of the CuBr multi-wavelength laser. FEM has the ability to deliver a steeply rising pulse of yellow light, and then rapidly decrease, delivering 2 mW of peak power exactly where it is needed." ■